Capsid inhibitors disrupt the HIV capsid, a protective protein shell for HIV's genetic material and replication enzymes.

Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP). Gilead presented data on two novel ...

A University of Utah professor is being recognized as one of Time's most influential people for his work in creating ...

Wesley Sundquist, a biochemist at University of Utah, and Tomas Cihlar, a virologist at Gilead, a biopharmaceutical company, have labored for more than a dozen years to turn one antiviral treatment, ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

They began by studying how HIV is built on a molecular level. They discovered that the capsid's structure is extremely sensitive, making it an ideal target for disrupting the virus' ability to ...

The impact of long-acting injectables (LAIs) for HIV was discussed at the 35th ESCMID Global conference in Vienna, Austria.

Of particular interest to us are systems where solid-state NMR methods provide unique (and often the only) insight into structure and dynamics: i) HIV-1 capsid protein assemblies whose function is ...

with particular emphasis on protein assemblies and the capsid cores. "Inositol phosphates are assembly co-factors for HIV-1," Robert Dick, Kaneil Zadrozny, Chaoyi Xu, Florian Schur, Terri Lyddon, ...

Sunlenca (lenacapavir), a first-in-class capsid inhibitor, is approved for heavily treatment-experienced patients with multidrug-resistant HIV, administered twice yearly in combination with other ...